Skip to main content

Table 1 Demographics and Baseline Characteristics (ITT Population)

From: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

 

Study 1

Study 2

  

MEDI-528

  

Parameter

Placebo

(n = 9)

0.3 mg/kg

(n = 9)

1 mg/kg

(n = 9)

3 mg/kg

(n = 9)

Placebo

(n = 4)

MEDI-528

50 mg (n = 7)

Mean age, years (range)

38.6 (22-63)

38.2 (18-61)

33.2 (19-57)

28.9 (19-55)

31.8 (19-47)

32.1 (19-39)

Female, n (%)

8 (88.9)

8 (88.9)

5 (55.6)

5 (55.6)

2 (50)

6 (85.7)

Race/Ethnicity, n (%)

      

   White/non-Hispanic

8 (88.9)

6 (66.7)

9 (100)

5 (55.6)

3 (75.0)

6 (85.7)

   White/Hispanic

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (14.3)

   Black

0 (0.0)

2 (22.2)

0 (0.0)

3 (33.3)

1 (25.0)

0 (0.0)

   Asian

0 (0.0)

0 (0.0)

0 (0.0)

1 (11.1)

0 (0.0)

0 (0.0)

   Multiracial

1 (11.1)

1 (11.1)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Mean weight, kg (range)

68.5 (52.0-93.9)

78.9 (58.2-99.7)

72.3 (43.0-99.1)

72.7 (57.6-97.7)

77.3 (57.7-93.2)

73.4 (52.7-97.3)

Mean (SD) FEV1 (L)*

2.8 (0.58)

2.8 (0.93)

3.2 (0.73)

3.4 (0.43)

3.3 (1.25)

2.8 (0.56)

Ever smoked, n (%)

7 (77.8)

1 (11.1)

1 (11.1)

0 (0.0)

1 (25.0)

2 (28.6)

Exacerbations in past year, no. (%)

      

   None

4 (44.4)

6 (66.7)

6 (66.7)

4 (44.4)

2 (50.0)

3 (42.9)

   1-2

5 (55.6)

3 (33.3)

2 (22.2)

5 (55.6)

2 (50.0)

4 (57.1)

   3-5

0 (0.0)

0 (0.0)

1 (11.1)

0 (0.0)

0 (0.0)

0 (0.0)

  1. *Measurements from evaluable subjects (those who received ≥7 or ≥4 doses of the study drug in study 1 and study 2, respectively); ITT = intent to treat (all randomized subjects); SD = standard deviation; FEV1 = forced expiratory volume in 1 second.